Clinical Investigation

Kidney International (1995) 48, 851–859; doi:10.1038/ki.1995.361

"Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis

Robert D Toto, Helen C Mitchell, Ronald D Smith, Hing-Chung Lee, Donald McIntire and William A Pettinger

Department of Internal Medidcine and Biostatistics, The University of Texas Southwestern Medical Center-Dallas, and The Dallas Nephrology Research Institute, Dallas, Texas; and Midwest Hypertension Research Center at Creighton, Omaha, Nebraska, USA

Correspondence: Robert D Toto MD, Department of Internal Medicine, The University of Texas Southwestern Medical Center-Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235-8856, USA.

Received 7 November 1994; Revised 17 April 1995; Accepted 17 April 1995.

Top

Abstract

"Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Hypertensive nephrosclerosis is a progressive renal disease and the leading cause of end-stage renal disease (ESRD) in blacks in the United States. It is generally believed that hypertensive renal injury is responsible for progressive renal failure; however, it is not known whether pharmacologic lowering of blood pressure to any level prevents progression of renal disease. Accordingly, we performed a long-term prospective randomized trial to determine whether "strict" [diastolic blood pressure (DBP) 65 to 80 mm Hg] versus "conventional" (DBP 85 to 95 mm Hg) blood pressure control is associated with a slower rate of decline in glomerular filtration rate. Eighty-seven non-diabetic patients (age 25 to 73; 68 black, 58 male) with long-standing hypertension (DBP greater than or equal to 95 mm Hg), chronic renal insufficiency (GFR less than or equal to 70 m/min/1.73 m2) and a normal urine sediment were studied. DBP was pharmacologically lowered to less than or equal to 80 mm Hg (3 of 4 consecutive measurements at 1 to 4 weeks intervals) after which patients were randomized. DBP and GFR (renal clearance of 125I-iothalamate) were measured at baseline, at three months and every six months post-randomization. The rate of decline in GFR (GFR slope, in ml/min/1.73 m2/year), estimated by the method of maximum likelihood in a mixed effects model, was the primary outcome variable. In a secondary analysis, 50% reduction in GFR (or a doubling of serum creatinine) from baseline, ESRD and death were combined. Also the rate of decline in GFR in blacks and non-blacks was compared. Mean follow-up was 40.5 plusminus 1.8 months in the "strict" and 42.2 plusminus2.1 month in the "conventional" groups. Mean follow-up DBP was 81 plusminus 1 mm Hg in the "strict" and 87 plusminus 1 mm Hg in the "conventional" groups (P < 0.0001, 95% C.I. for the difference -8.4 to -3.1). GFR slope was -0.31 plusminus 0.45 in the "strict" and -0.050 plusminus 0.50 ml/min/1.73 m2/year in the "conventional" group (P > 0.25, 95% C.I. for the difference -1.60 to 1.08). The mean slopes were not significantly different from zero. Twelve (7 with ESRD) of 42 "strict" and 7 (2 with ESRD) of 35 "conventional" (2 ESRD) patients experienced a clinical endpoint in the time to event analysis (P > 0.25). Mean follow-up DBP was 85 plusminus 1 in blacks and 79 plusminus 1 in non-blacks (P < 0.01, 95% C.I. 2.3 to 9.8); however, GFR slope in blacks (N = 58) was -0.016 plusminus 0.37 versus -0.27 plusminus 0.76 ml/min/1.73 m2/year in non-blacks (P > 0.25). We conclude that in hypertensive nephrosclerosis "strict" control of blood pressure to a mean DBP of 81 plusminus 0.8 mm Hg did not conserve renal function better than "conventional" control of blood pressure to a mean of 86.7 plusminus 1.1 mm Hg. However, both "strict" and "conventional" blood pressure control are associated with a very slow overall mean rate of decline in GFR. In addition, we found that long-term blood pressure lowering was associated with a similar slow rate of decline in GFR in blacks and non-blacks. Application of this quality of blood pressure control could significantly reduce the incidence of ESRD in the United States.

Top

References

  1. The National Institutes of Health U.S. Renal Data Systems Annual Report. U S Renal Data Systems 1993
  2. Blythe WD, Maddux FW: Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States form 1980–1986. Am J Kid Dis 28:33–37, 1991
  3. Moyer JH, Heider C, Pevey K, Ford RV: The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med 24:177–192, 1958 | PubMed |
  4. Magee JH, Unger AM, Richardson DW: Changes in renal function associated with drug or placebo therapy of human hypertension. Am J Med 36:795–804, 1964
  5. Shulman NB, Ford CE, Hall WD, Blaufox D, Simon D, Langford HB, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the Hypertension Detection and Follow-up study. Hypertension 13(Suppl I):I80–I93, 1989 | PubMed | ChemPort |
  6. Breckenridge A, Doller CT, Parry EHO: Prognosis of treated hypertension: Changes in life expectancy and causes of death between 1952 and 1967. Quart J Med 39:411–429, 1970
  7. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertension. N Engl Med 320:684–688, 1988
  8. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA 268:3085–3091, 1992 | Article | PubMed | ISI | ChemPort |
  9. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150:2073–2076, 1990 | Article | PubMed | ISI | ChemPort |
  10. Relman AS: Race and end-stage renal disease. N Engl Med 306:1290–1291, 1982
  11. Rostand SG, Kirk KA, Rutsky EA, Pate BA: Racial differences in the incidence of treatment for end-stage renal disease. N Engl Med 306:1276–1279, 1982
  12. Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease. Hypertension 13(Suppl I):I19–I27, 1993
  13. Eggers PW, Connerton R, McMullan M: The medicare experience with end-stage renal disease: Trends in incidence, prevalence, and survival. Health Care Fin Rev 5:69–88, 1984
  14. McClellan W, Tuttle E, Issa A: Racial differences in the incidence of hypertensive end-stage renal disease are not entirely explained by differences in the prevalence of hypertension. Am J Kid Dis 12:285–290, 1988
  15. Pettinger WA, Mitchell HE: Minoxidil—An alternative to nephrectomy for refractory hypertension. N Engl J Med 289:167–173, 1973
  16. Mitchell HE, Graham MR, Pettinger WA: Renal function during long-term treatment of hypertension with minoxidil: Comparison of benign and malignant hypertension. Ann In Med 93:676–681, 1980
  17. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202:116–122, 1967
  18. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 248:1465–1467, 1982
  19. Management Committee of the Australian Therapeutic Trial in Mild Hypertension: Untreated mild hypertension: A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet i:185–191, 1982
  20. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension III. Influence of age, diastolic pressure and prior cardiovascular disease; Further analysis of side effects. Circulation XLV:991–1003, 1972
  21. National High Blood Pressure Education Program (NHBPEP) Working Group Report. Bethesda, US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1990
  22. Luke RG: Can renal failure due to hypertension be prevented? Hypertension 18(Suppl 3):I139–I142, 1991
  23. Wolff FW, Lindeman RD: Effects of treatment in hypertension: Results of a controlled trial. J Chron Dis 19:227–240, 1966
  24. Bergstrom J, Alvestrand A, Bucht H, Gutierrez A: Progression of chronic renal failure in man is retarded with more frequent clinical follow-up and better blood pressure control. Clin Nephrol 25:1–6, 1986 | PubMed | ISI | ChemPort |
  25. Pettinger WA, Lee HC, Reisch J, Mitchell HC: Long-term improvement in renal function after short-term "strict" blood pressure control in hypertensive nephrosclerosis. Hypertension 89:766–772, 1989
  26. Perneger TV, Klag JJ, Feldman HI, Whelton PK: Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 269:1272–1277, 1993 | Article | PubMed | ISI | ChemPort |
  27. Israelit A, Long DL, White MG, Hull AR: Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I-iothalamate. Kidney Int 4:346–349, 1973 | PubMed | ISI | ChemPort |
  28. Levey AS: Measurement of renal function in chronic renal disease. Kidney Int 38:167–184, 1990 | PubMed | ISI | ChemPort |
  29. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38:963–974, 1982 | Article | PubMed | ISI | ChemPort |
  30. Klahr S, Levey A, Beck G, Caggiula A, Hunsicker L, Kusek J, Striker G: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl Med 330:877–884, 1994
  31. Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 26:861–868, 1984 | PubMed | ISI | ChemPort |
  32. Easterling RE: Racial factors in the incidence and causation of end-stage renal disease (ESRD). Trans Am Soc Artif Intern Organs 23:28–33, 1977 | PubMed |
  33. Shulman NB: Epidemiology of hypertension in blacks, in Hypertension in Blacks: Epidemiology, Pathophysiology and Treatment, edited by Hall WD, Saunders E, Shulman NB, Chicago, New York Medical Publishers, 1985, p 115
  34. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: Role of blood pressure. Kidney Int 35:670–674, 1989 | PubMed | ISI | ChemPort |
  35. Zuccchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452–458, 1992

Extra navigation

.
ADVERTISEMENT